Advertisement

Apoptosis induced by Bcl-2 antisense peptide acid in HL60 cells

  • Lei Xiaoyong
  • Zhang Huan
  • He Dongmei
Original Articles

Abstract

Objective

To study the differences and similarties of the antisense drugs with different structures on the biological functions of HL60 cells.

Methods

Cytotoxic effects were measured by cell viability assay. The expression levels of protein were assayed by immunofluorecence using fluoresce isothiocyanate label. The morphological changes in apoptotic cells were observed. Flow cytometric analysis of DNA fragmentation was also performed.

Results

Antisense peptide nucleic acid (PNA) targeting the coding region of the Bcl-2 mRNA could effectively inhibit the growth of HL60 cells, down-regulate the synthesis of Bcl-2 protein and induce apoptosis. After HL60 cells were treated with 10 μmol/L Bcl-2 antisense PNA or antisense oligonucleotide for 72 h respectively, apoptotic rates of HL60 cells were 17.80±1.53 and 13.17±1.12, respectively (P<0.05).

Conclusion

Antisense PNA targeting the coding region of Bcl-2 mRNA may have stronger antisense effects than the antisense oligonucleotides and could induce apoptosis of HL60 cells.

Key words

Bcl-2 antisense peptide nucleic acid antisense oligonucleotide HL60 cells apoptosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kirkland MA, O'Brien SG, Goldman JM. Antisense therapeutics in haematological malignancies. Br J Haematol, 1994, 87: 447–452.CrossRefPubMedGoogle Scholar
  2. 2.
    Reed JC, Stein C, Subasinghe C,et al. Antisense-mediated inhibition of bcl2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res, 1990, 50: 6565–6570.PubMedGoogle Scholar
  3. 3.
    Bilim V, Kasahara T, Noboru H,et al. Caspase involved synergistic cytotoxicity of Bcl-2 antisense oligonucleotides and adriamycin on transitional cell cancer cells. Cancer Lett, 2000, 155: 191–198.CrossRefPubMedGoogle Scholar
  4. 4.
    Bloem A, Lockhorst H. Bcl-2 antisense therapy in multiple myeloma. Pathol Biol, 1999, 47: 216–220.PubMedGoogle Scholar
  5. 5.
    Webb A, Cunningham D, Cotter F,et al. Bcl-2 antisense therapy in patients with non-Hodgkin lymphoman. Lancet, 1997, 349:1137–1141.CrossRefPubMedGoogle Scholar
  6. 6.
    Demidov VV, Potaman VN, Frank-Kamenetskii MD,et al. Stability of peptide nucleic acids in human serum and cellular extracts. Biochemical Pharmacology, 1994, 48: 1310–1313.CrossRefPubMedGoogle Scholar
  7. 7.
    Mologni L, Nielsen PE, Gambacorti-Passerini C. In vitro transcriptional and translational block of the Bcl-2 gene operated by peptide nucleic acid. Biochem biophys Res Commun, 1999, 264: 537–543.CrossRefPubMedGoogle Scholar
  8. 8.
    Lei XY, Zhang H. Effect of Bcl-2 antisense oligonucleotide targeting different region of Bcl-2 mRNA on drug-sensitivity of leukemia cells. Chin J Pharmacol Ther, 2001, 6: 1–4.Google Scholar
  9. 9.
    Lei XY, Zhang Y. Lin J. Induction of apoptosis in HL60 cells by a new antisense oligonucleotide targeting the Bcl-2 coding sequences. Journal of Jian University, 2001, 22: 125–128.Google Scholar
  10. 10.
    Miayake H, Tolcher A, Gleave ME. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J Natl Cancer Inst, 2000, 92: 34–41.CrossRefPubMedGoogle Scholar
  11. 11.
    Doyle DF, Braasch DA, Simmons CG,et al. Inhibition of gene expression inside cells by peptide nucleic acids: effect of mRNA target sequence, mismatched bases, and PNA length. Biochemistry, 2001, 40: 53–64.CrossRefPubMedGoogle Scholar
  12. 12.
    Malchere C, Verheijen J, Laan S,et al. A short phospholidester window is sufficent to direct RNase H-dependent RNA cleavage by antisense peptide nucleic acid. Antisense Nucleic Acid Drug Dev, 2000, 10: 463–468.CrossRefPubMedGoogle Scholar

Copyright information

© Editorial Office of The Chinese-German Journal of Clinical Oncology 2002

Authors and Affiliations

  1. 1.Institute of Pharmacy and PharmacologyNahua UniversityHengyangChina
  2. 2.Institute of HematologyJinan UniversityGuangzhouChina
  3. 3.Institute of HematologyJinan UniversityGuangzhouChina

Personalised recommendations